Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes | Yanai | Cardiology Research
Forest plots of Hazard Ratios for all-cause-mortality, 3-point MACE,... | Download Scientific Diagram
European Society of Cardiology/Heart Failure Association Position Paper on the Role and Safety of New Glucose-lowering Drugs in Patients with Heart Failure | Digimed Updates
The cumulative event rates of three-point MACE (a) and all-cause death... | Download Scientific Diagram
Nutrients | Free Full-Text | Urinary Phosphorus Excretion and Cardiovascular Outcomes in Patients with Pre-Dialysis Chronic Kidney Disease: The KNOW-CKD Study
BJD
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management. - ppt download
Henry Han , MBBS, MD on X: "Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With
SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials - PACE-CME
HEART Score
JCM | Free Full-Text | Contemporary Cardiovascular Risk Assessment for Type 2 Diabetes Including Heart Failure as an Outcome: The Fremantle Diabetes Study Phase II
د. ثامر العيسى on X: "In event-driven PIONEER 6 CV safety trial with oral semaglutide, non-significant 21% 3-point MACE was found with significant 50% reduction in CV mortality and all-cause mortality in
JCM | Free Full-Text | GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Summary: T2DM and Cardiovascular Outcomes - PACE-CME
CV Outcomes-The Data | VASCEPA® (icosapent ethyl)
EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... | Download Scientific Diagram
Major adverse cardiac event (MACE) end point frequencies up to 2-year... | Download Scientific Diagram
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review | BMC Medical Research Methodology | Full Text
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials | Cardiovascular Diabetology | Full Text
MACE Benefit | INVOKANA® (canagliflozin) HCP
Kaplan-Meier-Curves and cumulative event tables for all-cause... | Download Scientific Diagram
EMPRISE study outcomes of interest. 3P‐MACE: three‐point major... | Download Scientific Diagram
MACE Benefit | INVOKANA® (canagliflozin) HCP
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ( CVOTs ) in Diabetes | PPT
